ClinicalTrials.gg
TerminatedNCT01271010Updated Mar 20, 2018Results posted

A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

A Phase 4 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Terminated at 10 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-20.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
38th of 145
89 · median 49
Started
2011
with 7 others
Phase 4
3 of 155
none open now
Registered
111th of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 38th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 4, and was the 111th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of previously untreated B-cell CLL confirmed immunophenotypically
  • For participants, age 60-70 years: Cumulative Illness Rating Scale (CIRS) comorbidity score less than or equal to (\</=) 6
  • Binet stage B, C or A with progression
  • greater than or equal to (>/=) 12 months
  • (ECOG) performance status (PS) 0-2
  • Women of child bearing potential and men should agree to use highly reliable method throughout the treatment period and within 12 months after treatment completion

Exclusion criteria

Exclusion Criteria:

  • Participants with small-cell lymphoma
  • Participants with auto-immune hemolytic anemia
  • Concomitant malignant disease during enrollment, except basal cell carcinoma of the skin
  • Chemotherapy for concomitant malignant disease given within 12 months prior to study enrollment
  • Participants with Richter's Syndrome
  • Participants with symptomatic infection
  • Any infection that could not be cured prior to enrollment, including (HIV) infection
  • less than (\<) 30 milliliters per minute (mL/min)
  • Participants with congestive heart failure (CHF) (NYHA) III-IV
  • Participants with liver failure and acute hepatitis of any etiology
  • Any other medical or mental condition which may preclude from receiving the entire course of protocol specified treatment or signing the
  • History of an anaphylactic reaction to murine antibodies, proteins, or any other ingredient of rituximab
  • Pregnancy and breast-feeding women
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Rituximab + Fludarabine + Cyclophosphamide

    Participants received rituximab 375 milligrams per square meter (mg/m\^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

Interventions

  • Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.

  • Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.

  • Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.

    Also known as: MabThera

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Remission

    Complete remission was defined as the disappearance of all signs of disease.

    Time frame: Up to approximately 5 years

  2. Percentage of Participants With Disease Progression

    Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

    Time frame: Up to approximately 5 years

  3. Percentage of Participants With Stable Disease

    Stable disease was defined as not meeting the criteria for partial remission or disease progression

    Time frame: Up to approximately 5 years

  4. Percentage of Participants With Partial Remission

    Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  5. Duration of Response

    Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  6. Progression-free Survival

    Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

    Time frame: Up to approximately 5 years

  7. Event-free Survival

    Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  8. Overall Survival

    Overall survival was defined as the time period from the first day of study treatment to participant death.

    Time frame: Up to approximately 5 years

  9. Percentage of Participants With Phenotypic Remission

    Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.

    Time frame: Up to approximately 5 years

  10. Percentage of Participants With Adverse Events (AEs) and Serious AEs

    An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.

    Time frame: Up to approximately 5 years

07

Results

Posted Mar 20, 2018

Participant flow

Participant flow — Overall Study
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started89
Completed28
Not completed61
Withdrew: Reason not specified11
Withdrew: Start of new cll therapy1
Withdrew: Protocol violation1
Withdrew: Death2
Withdrew: Progression and relapse of disease1
Withdrew: Withdrawal by subject18
Withdrew: Disease progression27

Outcome measures

PrimaryPercentage of Participants With Complete Remission

Complete remission was defined as the disappearance of all signs of disease.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Complete Remission49.3
PrimaryPercentage of Participants With Disease Progression

Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Disease Progression5.5
PrimaryPercentage of Participants With Stable Disease

Stable disease was defined as not meeting the criteria for partial remission or disease progression

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Stable Disease4.1
PrimaryPercentage of Participants With Partial Remission

Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Partial Remission
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Partial Remission41.1
PrimaryDuration of Response

Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Duration of Response
daysRituximab + Fludarabine + Cyclophosphamide
Duration of ResponseNA (NA to NA)
PrimaryProgression-free Survival

Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Progression-free Survival
daysRituximab + Fludarabine + Cyclophosphamide
Progression-free SurvivalNA (NA to NA)
PrimaryEvent-free Survival

Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Event-free Survival
daysRituximab + Fludarabine + Cyclophosphamide
Event-free Survival1567 (1036 to NA)
PrimaryOverall Survival

Overall survival was defined as the time period from the first day of study treatment to participant death.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Overall Survival
daysRituximab + Fludarabine + Cyclophosphamide
Overall SurvivalNA (NA to NA)
PrimaryPercentage of Participants With Phenotypic Remission

Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Phenotypic Remission
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Phenotypic Remission66.7
PrimaryPercentage of Participants With Adverse Events (AEs) and Serious AEs

An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious AEs
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Non-serious AEs78.65
Serious AEs13.48

Adverse events

Collected over Up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Fludarabine + Cyclophosphamide—12/89 (13.5%)70/89 (78.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventRituximab + Fludarabine + Cyclophosphamide
Herpes zosterInfections and infestations2/89
PneumoniaRespiratory, thoracic and mediastinal disorders2/89
AppendicitisInfections and infestations1/89
PeritonitisInfections and infestations1/89
Proctitis infectiousInfections and infestations1/89
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/89
Squamous cell carcinoma of lungRespiratory, thoracic and mediastinal disorders1/89
AgranulocytosisBlood and lymphatic system disorders1/89
Neuroendocrine tumourEndocrine disorders1/89
Abdominal painGastrointestinal disorders1/89
Most frequent other events
Most frequent other events
EventRituximab + Fludarabine + Cyclophosphamide
Neutrophil count decreasedInvestigations37/89
White blood cell count decreasedInvestigations20/89
ThrombocytopeniaBlood and lymphatic system disorders10/89
AnaemiaBlood and lymphatic system disorders9/89
NauseaGastrointestinal disorders9/89
Respiratory tract infectionInfections and infestations8/89
LeukocytosisBlood and lymphatic system disorders5/89

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Rituximab + Fludarabine + Cyclophosphamide
Mean55.9 ± 6.39
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Fludarabine + Cyclophosphamide
Female31
Male58
08

Study locations

10 sites
  • The order of Honour pin Irkutsk regional clinical hospital; Hematology Department
    Irkutsk, 664079, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • Regional Clinical Oncology Despensary #1; Hematology Department
    Krasnodar, 350040, Russian Federation
  • N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis
    Moscow, 115478, Russian Federation
  • City Clinical Hospital After Botkin; Hematology
    Moscow, 125101, Russian Federation
  • City Clinical Hospital #15; Hematology department
    Saint-Petersburg, 198205, Russian Federation
  • Leningrad Regional Clinical Hospital; Hematology #1
    St Petersburg, Russian Federation
  • Saint-Petersburg SHI City Clinical Hospital #31
    St. Petersburg, 197110, Russian Federation
  • GUZ Tula Regioanal Clinical Hospital; Hematology
    Tula, 300053, Russian Federation
  • Republican clinical hospital named after G.G. Kuvatov
    UFA, 450005, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2011 to primary completion in May 2016, 58 months.

Results were first posted in Mar 2018, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2011
First posted
Jan 6, 2011
StartActual
Jun 17, 2011
Primary completionActual
May 4, 2016
CompletionActual
May 4, 2016
Results first posted
Mar 20, 2018
Last update
Mar 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01271010
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 6, 2011
Start date
Jun 17, 2011
Primary completion
May 4, 2016
Completion
May 4, 2016
Results posted
Mar 20, 2018
Last update
Mar 20, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab

Start the discussion